Coral Gables, FLORIDA3 Active Studies

Neuroendocrine Tumors Clinical Trials in Coral Gables, FLORIDA

Find 3 actively recruiting neuroendocrine tumors clinical trials in Coral Gables, FLORIDA. Connect with local research sites and explore new treatment options.

3
Active Trials
1
Sponsors
264
Enrolling

Recruiting Neuroendocrine Tumors Studies in Coral Gables

About Neuroendocrine Tumors Clinical Trials in Coral Gables

Neuroendocrine tumors (NETs) develop from hormone-producing cells and can occur in many organs, most commonly the gastrointestinal tract and lungs. They range from slow-growing to aggressive. Treatment includes surgery, somatostatin analogs, targeted therapy, and peptide receptor radionuclide therapy.

There are currently 3 neuroendocrine tumors clinical trials recruiting participants in Coral Gables, FLORIDA. These studies are seeking a combined 264 participants. Research is being sponsored by National Cancer Institute (NCI). Clinical trial participation is free and participants receive study-related medical care at no cost.

Neuroendocrine Tumors Clinical Trials in Coral Gables — FAQ

Are there neuroendocrine tumors clinical trials in Coral Gables?

Yes, there are 3 neuroendocrine tumors clinical trials currently recruiting in Coral Gables, FLORIDA. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Coral Gables?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Coral Gables research site will contact you about next steps.

Are clinical trials in Coral Gables free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Coral Gables studies also compensate for your time and travel.

What neuroendocrine tumors treatments are being tested?

The 3 active trials in Coral Gables are testing new therapies including novel drugs, biologics, and treatment approaches for neuroendocrine tumors.

Data updated March 2, 2026 from ClinicalTrials.gov